Endothelial cell dysfunction is a outstanding function of diabetic cardiovascular issues, and endothelial cell senescence is taken into account to be an vital contributor to endothelial dysfunction. Discoidin area receptor 1 (DDR1) has been reported to be concerned in atherogenesis and cerebral ischemia/reperfusion damage. In this examine, we aimed to discover the function of DDR1 in endothelial cell senescence underneath diabetic situations and elucidate the underlying mechanisms.
A diabetic rat mannequin was established by a single intraperitoneal injection of streptozocin (STZ) (60 mg/kg), which confirmed a rise in senescence-associated β-galactosidase (SA-β-gal) staining sign of thoracic aortic endothelium, impaired vascular construction and performance, accompanied by an up-regulation of DDR1. Next, we verified the function of DDR1 in endothelial senescence and the underlying mechanisms in excessive glucose-treated human umbilical vein endothelial cells (HUVECs).
Consistent with the in vivo findings, excessive glucose induced endothelial senescence, impaired endothelial operate and elevated DDR1 expression, accompanied by the elevation of senescence-related genes p53 and p21 expression, and these results have been reversed by DDR1 siRNA. DDR1 has been documented to be a possible goal of miR-199a-3p.
Here, we discovered that miR-199a-3p was down-regulated by excessive glucose in the aorta tissue and HUVECs, whereas miR-199a-3p mimic considerably suppressed elevated endothelial senescence and elevated DDR1 induced by excessive glucose.
In conclusion, our information demonstrated that miR-199a-3p/DDR1/p53/p21 signaling pathway was concerned in endothelial senescence underneath diabetic situations, and therapeutic concentrating on DDR1 could be exploited to inhibit endothelial senescence owing to excessive glucose publicity.
Study of blood glucose and insulin infusion charge in real-time in diabetic rats utilizing a synthetic pancreas system
Artificial pancreas system (APS) is an rising new therapy for kind 1 diabetes mellitus. The intention of this examine was to develop a rat APS as a analysis software and show its software. We established a rat APS utilizing Medtronic Minimed Pump 722, Medtronic Enlite sensor, and the open synthetic pancreas system as a controller.
We examined totally different dilutions of Humalog (100 items/ml) in saline ranged from 1:Three to 1:20 and decided that 1:7 dilution works effectively for rats with ~500g body weight. Blood glucose ranges (BGL) of diabetic rats fed with chow food plan (58% carbohydrate) whose BGL was managed by the closed-loop APS for the overall period of 207h have been in euglycemic vary (70-180 mg/dl) for 94.5% of the time with 2.1% and three.4% for hyperglycemia (>180mg/dl) and hypoglycemia (<70 mg/dl), respectively.
Diabetic rats fed with Sucrose pellets (94.8% carbohydrate) for the experimental period of 175h have been in euglycemic vary for 61% of the time with 35% and 4% for hyperglycemia and hypoglycemia, respectively. Heathy rats fed with chow food plan confirmed nearly a straight line of BGL ~ 95 mg/dl (common 94.Eight mg/dl) throughout the complete experimental interval (281h), which was minimally altered by meals consumption.
In the wholesome rats, feeding sucrose pellets induced larger vary of BGL in excessive and low ranges however nonetheless inside euglycemic vary (99.9%). Next, to check how wholesome and diabetic rats deal with supra-physiological concentrations of glucose, we intraperitoneally injected varied quantities of 50% dextrose (2, 3, 4g/kg) and monitored BGL.
Duration of hyperglycemia after injection of 50% dextrose in any respect three totally different concentrations was considerably larger for wholesome rats than diabetic rats, suggesting that insulin infusion by APS was superior in decreasing BGL as in comparison with pure insulin launched from pancreatic β-cells. Ex vivo research confirmed that islets remoted from diabetic rats have been nearly fully devoid of pancreatic β-cells however with intact α-cells as anticipated.
Lipid droplet deposition in the liver of diabetic rats was considerably decrease with greater ranges of triacylglyceride in the blood as in comparison with these of wholesome rats, suggesting lipid metabolism was altered in diabetic rats. However, glycogen storage in the liver decided by Periodic acid-Schiff staining was not altered in diabetic rats as in comparison with wholesome rats.
A rat APS could also be used as a strong software not solely to check alterations of glucose and insulin homeostasis in real-time attributable to food plan, train, hormones, or antidiabetic brokers, but in addition to check mathematical and engineering fashions of blood glucose prediction or new algorithms for closed-loop APS.
A evaluate on community pharmacology based mostly phytotherapy in treating diabetes– An environmental perspective
Diabetes has grow to be frequent life-style dysfunction related to weight problems and cardiovascular ailments. Environmental components like bodily inactivity, polluted environment and unhealthy weight-reduction plan additionally performs an important function in diabetes pathogenesis.
As the present anti-diabetic medicine possess unprecedented unintended effects, conventional natural drugs can be utilized another remedy. The paramount problem with the natural formulation utilization is the dearth of standardized process, entangled with little data on drug security and mechanism of drug motion. Heavy metallic contamination is a significant environmental hazard the place crops are likely to accumulate poisonous metals like nickel, chromium and lead by industrial and agricultural actions.
It turns into inappropriate to make use of these crops for phytotherapy as it could have an effect on the human well being on long run consumption. This evaluate focus on concerning the environmental threat components associated to diabetes and higher implication of medicinal crops in anti-diabetic remedy utilizing community pharmacology. It is an in silico analytical software that helps to unravel the multi-targeted motion of natural formulations wealthy in secondary metabolites.
Human iPS Cell Line (Type 2 Diabetes) |
|||
| CSC-00849L | Creative Bioarray | One Frozen vial | Ask for price |
Human Muscle Myoblasts, Diabetes Type I |
|||
| ABC-TC3956 | AcceGen | 1 vial | Ask for price |
|
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
|||
Human Muscle Myoblasts, Diabetes Type II |
|||
| ABC-TC3957 | AcceGen | 1 vial | Ask for price |
|
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
|||
Human Type 1 Diabetes Leukopak |
|||
| ABC-TC4310 | AcceGen | 1 pack | Ask for price |
|
Description: RI dependent diabetes, or Type 1 Diabetes is caused by the pancreas producing little to no RI. |
|||
HighQC™ Human IPS Cell (Type 2 Diabetes) |
|||
| ABC-SC0005T | AcceGen | 1 vial | Ask for price |
|
Description: Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells . The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body. iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells. |
|||
Human Type I Diabetes PB Plasma |
|||
| ABC-TC4264 | AcceGen | 1 vial | Ask for price |
|
Description: Type I Diabetes peripheral blood plasma is obtained by centrifugation of the Type I Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type I PB plasma is available upon request. |
|||
Human Type II Diabetes PB Plasma |
|||
| ABC-TC4266 | AcceGen | 1 vial | Ask for price |
|
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request. |
|||
Preadipocytes, visc 1M cells, Diabetes Type I |
|||
| LOPT-5023 | Westburg | each | 1155.54 EUR |
Preadipocytes, visc 1M cells, Diabetes Type II |
|||
| LOPT-5024 | Westburg | each | 1155.54 EUR |
Type I Diabetes Serum, Human Donor |
|||
| MBS170481-1Sample | MyBiosource | 1Sample | 310 EUR |
Type I Diabetes Serum, Human Donor |
|||
| MBS170481-5Samples | MyBiosource | 5Samples | 960 EUR |
Type I Diabetes Serum, Human Donor |
|||
| MBS170481-5x5Samples | MyBiosource | 5x5Samples | 4110 EUR |
Type II Diabetes Serum, Human Donor |
|||
| MBS170482-1Sample | MyBiosource | 1Sample | 310 EUR |
Type II Diabetes Serum, Human Donor |
|||
| MBS170482-5Samples | MyBiosource | 5Samples | 960 EUR |
Type II Diabetes Serum, Human Donor |
|||
| MBS170482-5x5Samples | MyBiosource | 5x5Samples | 4110 EUR |
Preadipocytes, subcu 1M cells, Diabetes Type I |
|||
| LOPT-5021 | Westburg | each | 782.64 EUR |
Preadipocytes, subcu 1M cells, Diabetes Type II |
|||
| LOPT-5022 | Westburg | each | 782.64 EUR |
Plasma - Type II Diabetes - Human Patient |
|||
| MBS170491-1Sample | MyBiosource | 1Sample | 310 EUR |
Plasma - Type II Diabetes - Human Patient |
|||
| MBS170491-5Samples | MyBiosource | 5Samples | 1005 EUR |
Plasma - Type II Diabetes - Human Patient |
|||
| MBS170491-5x5Samples | MyBiosource | 5x5Samples | 4310 EUR |
Plasma - Type I Diabetes - Patient Sample |
|||
| MBS170490-1Sample | MyBiosource | 1Sample | 310 EUR |
Plasma - Type I Diabetes - Patient Sample |
|||
| MBS170490-5Samples | MyBiosource | 5Samples | 1005 EUR |
Plasma - Type I Diabetes - Patient Sample |
|||
| MBS170490-5x5Samples | MyBiosource | 5x5Samples | 4310 EUR |
Single Donor Human Type II Diabetes Semen |
|||
| IRHUSMSDIBTII1ML | Innovative research | each | 842 EUR |
|
Description: Single Donor Human Type II Diabetes Semen |
|||
Single Donor Human Type I Diabetes Urine |
|||
| IRHUURESDIBTI250ML | Innovative research | each | 1063 EUR |
|
Description: Single Donor Human Type I Diabetes Urine |
|||
Single Donor Human Type I Diabetes Urine |
|||
| IRHUURESDIBTI50ML | Innovative research | each | 439 EUR |
|
Description: Single Donor Human Type I Diabetes Urine |
|||
Single Donor Human Type II Diabetes Urine |
|||
| IRHUURESDIBTII250ML | Innovative research | each | 1063 EUR |
|
Description: Single Donor Human Type II Diabetes Urine |
|||
Single Donor Human Type II Diabetes Urine |
|||
| IRHUURESDIBTII50ML | Innovative research | each | 439 EUR |
|
Description: Single Donor Human Type II Diabetes Urine |
|||
Single Donor Human Type II Diabetes Semen |
|||
| MBS8421302-1mL | MyBiosource | 1mL | 1045 EUR |
Single Donor Human Type II Diabetes Semen |
|||
| MBS8421302-5x1mL | MyBiosource | 5x1mL | 4460 EUR |
Single Donor Human Type I Diabetes Urine |
|||
| MBS8421330-250mL | MyBiosource | 250mL | 1285 EUR |
Single Donor Human Type I Diabetes Urine |
|||
| MBS8421330-50mL | MyBiosource | 50mL | 595 EUR |
Single Donor Human Type I Diabetes Urine |
|||
| MBS8421330-5x250mL | MyBiosource | 5x250mL | 5540 EUR |
Single Donor Human Type II Diabetes Urine |
|||
| MBS8421331-250mL | MyBiosource | 250mL | 1285 EUR |
Single Donor Human Type II Diabetes Urine |
|||
| MBS8421331-50mL | MyBiosource | 50mL | 595 EUR |
Single Donor Human Type II Diabetes Urine |
|||
| MBS8421331-5x250mL | MyBiosource | 5x250mL | 5540 EUR |
Semen, Single Human Donor - Type II Diabetes |
|||
| MBS173503-1Sample | MyBiosource | 1Sample | 815 EUR |
Semen, Single Human Donor - Type II Diabetes |
|||
| MBS173503-5x1Sample | MyBiosource | 5x1Sample | 3455 EUR |
Whole Blood - Type I Diabetes - Patient Sample |
|||
| MBS170486-1Sample | MyBiosource | 1Sample | 310 EUR |
Whole Blood - Type I Diabetes - Patient Sample |
|||
| MBS170486-5x1Sample | MyBiosource | 5x1Sample | 4310 EUR |
Whole Blood - Type II Diabetes - Patient Sample |
|||
| MBS170487-1Sample | MyBiosource | 1Sample | 310 EUR |
Whole Blood - Type II Diabetes - Patient Sample |
|||
| MBS170487-5x1Sample | MyBiosource | 5x1Sample | 4310 EUR |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type I |
|||
| LOCC-2919 | Westburg | each | 1920.94 EUR |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type II |
|||
| LOCC-2920 | Westburg | each | 1920.94 EUR |
HighQC™ Human IPS Cell (Episomal/ Diabetes Type II/ Adipose) |
|||
| ABC-SC0011T | AcceGen | 1 vial | Ask for price |
|
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
|||
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type I |
|||
| LOCC-2914 | Westburg | each | 1888.07 EUR |
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type II |
|||
| LOCC-2916 | Westburg | each | Ask for price |
HighQC™ Human IPS Cell (IPSC From PBMC/ Diabetes Type II/ Episomal) |
|||
| ABC-SC0009T | AcceGen | 1 vial | Ask for price |
|
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
|||
D-HCAEC – Diseased Human Coronary Artery Endothelial – Diabetes Type II |
|||
| LOCC-2922 | Westburg | each | 1884.64 EUR |
Human Type I Diabetes Peripheral Blood Mononuclear Cells |
|||
| ABC-TC4263 | AcceGen | 1 vial | Ask for price |
|
Description: Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type I PBMCs is available upon request. |
|||
Human Type II Diabetes Peripheral Blood Mononuclear Cells |
|||
| ABC-TC4265 | AcceGen | 1 vial | Ask for price |
|
Description: Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays. A peripheral blood mononuclear cell is defined as any blood cell with a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. The lymphocyte population consists of CD4+ and CD8+ T cells, B cells and Natural Killer cells, CD14+ Monocytes, and Basophils/Neutrophils/Eosinophils/Dendritic cells. These cells are often extracted from whole blood or from leukopacks using ficoll, a hydrophilic polysaccharide that separates layers of blood, with monocytes and lymphocytes forming a buffy coat under a layer of plasma.Samples from each donor are tested via PCR to confirm non-reactivity. Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type II PBMCs is available upon request. |
|||
D-Adipose-Derived stem cells, human, Type I Diabetes |
|||
| LOPT-5007 | Westburg | each | 748.19 EUR |
D-Adipose-Derived stem cells, human, Type II Diabetes |
|||
| LOPT-5008 | Westburg | each | 748.19 EUR |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type I |
|||
| LOCC-2917 | Westburg | each | 1880.03 EUR |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type II |
|||
| LOCC-2918 | Westburg | each | 1880.03 EUR |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type I |
|||
| LOCC-2927 | Westburg | each | 1299.42 EUR |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type II |
|||
| LOCC-2928 | Westburg | each | Ask for price |
HighQC™ Human IPS Cell (IPSC From Fibroblast/ Diabetes Type II/ Episomal) |
|||
| ABC-SC0010T | AcceGen | 1 vial | Ask for price |
|
Description: Gentaur is is proud to offer human iPS cell lines derived from the human dermal fibroblasts from patients with Type 2 Diabetes (T2D). The pertinent donor information is available upon request. These iPS cells are established from a single clone and expanded in feeder-free conditions. Normal human iPS cell lines are also available as separate products . We also provide custom iPSC generation and iPSC differentiation services to meet your needs. |
|||
D-HCAEC – Diseased Human Coronary Artery Endothelial Cells – Diabetes Type I |
|||
| LOCC-2921 | Westburg | each | 1884.64 EUR |
D-HEK-Ad – Diseased Human Adult Epidermal Keratinocytes – Diabetes Type II |
|||
| LOCC-2926 | Westburg | each | 841.52 EUR |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type I |
|||
| LOCC-2923 | Westburg | each | 1920.94 EUR |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type II |
|||
| LOCC-2924 | Westburg | each | Ask for price |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type II |
|||
| LOCC-2913 | Westburg | each | 1935.75 EUR |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type I |
|||
| LOCC-2915 | Westburg | each | Ask for price |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type I |
|||
| LOCC-2929 | Westburg | each | 1169.49 EUR |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type II |
|||
| LOCC-2930 | Westburg | each | Ask for price |
D-RPTEC – Diseased Human Renal Proximal Tubule Epithelial Cells – Diabetes Type II |
|||
| LOCC-2925 | Westburg | each | 2091.71 EUR |
Linearity FD Special Diabetes |
|||
| K889M-5 | Audit MicroControls | 5 x 2 mL | 374 EUR |
HighQC™ Human Bone Marrow Derived Mesenchymal Stem Cell/ Type II Diabetes Patient |
|||
| ABC-SC0027T | AcceGen | 1 vial | Ask for price |
|
Description: Human MSCs (Bone Marrow Derived) from a single adult donor clinically diagnosed with Type II Diabetes. The MSCs are compatible with our MSC Expansion Medium for Bone Marrow Derived MSCs.All of the cells provided are tested and are negative for HIV-1, HIV-2, Hepatitis B and Hepatitis C as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination. |
|||
Human Diabetes Lung Tissue Lysate |
|||
| IHULGDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Lung Tissue Lysate |
|||
Single Donor Human Diabetes Serum |
|||
| ISERSDIB | Innovative research | each | 209 EUR |
|
Description: Single Donor Human Diabetes Serum |
|||
Single Donor Human Diabetes Serum |
|||
| MBS8421607-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Lung Tissue Lysate |
|||
| MBS8414460-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Lung Tissue Lysate |
|||
| MBS8414460-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Colon Tissue Lysate |
|||
| IHUCLNDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Colon Tissue Lysate |
|||
Human Diabetes Ileum Tissue Lysate |
|||
| IHUILMDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Ileum Tissue Lysate |
|||
Single Donor Human Diabetes Plasma |
|||
| IPLASDIB | Innovative research | each | 209 EUR |
|
Description: Single Donor Human Diabetes Plasma |
|||
Single Donor Human Diabetes Plasma |
|||
| MBS8421060-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Ileum Tissue Lysate |
|||
| MBS8413586-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Ileum Tissue Lysate |
|||
| MBS8413586-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Colon Tissue Lysate |
|||
| MBS139594-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Colon Tissue Lysate |
|||
| MBS139594-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Jejunum Tissue Lysate |
|||
| IHUJEJDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Jejunum Tissue Lysate |
|||
Human Diabetes Stomach Tissue Lysate |
|||
| IHUSTDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Stomach Tissue Lysate |
|||
Human Diabetes Jejunum Tissue Lysate |
|||
| MBS8413808-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Jejunum Tissue Lysate |
|||
| MBS8413808-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Stomach Tissue Lysate |
|||
| MBS8420033-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Stomach Tissue Lysate |
|||
| MBS8420033-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Duodenum Tissue Lysate |
|||
| IHUDUODIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Duodenum Tissue Lysate |
|||
Human Diabetes Pancreas Tissue Lysate |
|||
| IHUPCSDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Pancreas Tissue Lysate |
|||
Human Diabetes Pancreas Tissue Lysate |
|||
| MBS8416917-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Pancreas Tissue Lysate |
|||
| MBS8416917-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Duodenum Tissue Lysate |
|||
| MBS8410767-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Duodenum Tissue Lysate |
|||
| MBS8410767-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes Esophagus Tissue Lysate |
|||
| IHUESOPDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Esophagus Tissue Lysate |
|||
Human Diabetes Esophagus Tissue Lysate |
|||
| MBS8411234-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Esophagus Tissue Lysate |
|||
| MBS8411234-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Single Donor HumanType I Diabetes Semen |
|||
| IRHUSSMDIBTI1 | Innovative research | each | 842 EUR |
|
Description: Single Donor HumanType I Diabetes Semen |
|||
Single Donor HumanType I Diabetes Semen |
|||
| MBS8421310-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
| IHUADPTVDIBTL100UG | Innovative research | each | 2663 EUR |
|
Description: Human Diabetes AdiposeVisceral Tissue Lysate |
|||
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
| MBS136954-01mg | MyBiosource | 0.1mg | 3320 EUR |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
| MBS136954-5x01mg | MyBiosource | 5x0.1mg | 14765 EUR |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
| IHUSKMDIBTL100UG | Innovative research | each | 1413 EUR |
|
Description: Human Diabetes Skeletal Muscle Tissue Lysate |
|||
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
| MBS8419496-01mg | MyBiosource | 0.1mg | 1810 EUR |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
| MBS8419496-5x01mg | MyBiosource | 5x0.1mg | 7965 EUR |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
| IHUADPTSDIBTL100UG | Innovative research | each | 2663 EUR |
|
Description: Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
| MBS136950-01mg | MyBiosource | 0.1mg | 3320 EUR |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
| MBS136950-5x01mg | MyBiosource | 5x0.1mg | 14765 EUR |
Diabetes Drug Leads Bioactive Peptide Library |
|||
| L-012 | PHOENIX PEPTIDE | 160 peptides | 7938 EUR |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
| IHUPCSDIBTLM100UG | Innovative research | each | 1199 EUR |
|
Description: Human Diabetes Pancreas Lysate Membrane Fraction |
|||
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
| MBS8416918-01mg | MyBiosource | 0.1mg | 1550 EUR |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
| MBS8416918-5x01mg | MyBiosource | 5x0.1mg | 6780 EUR |
Linearity FLQ Special Diabetes for Roche Systems |
|||
| K929M-5 | Audit MicroControls | 5 x 2 mL | 374 EUR |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
| MBS640656-5Slides | MyBiosource | 5Slides | 930 EUR |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
| MBS640656-5x5Slides | MyBiosource | 5x5Slides | 3955 EUR |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
| MBS657041-1mg | MyBiosource | 1mg | 820 EUR |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
| MBS657041-5x1mg | MyBiosource | 5x1mg | 3470 EUR |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
| MBS657133-1mg | MyBiosource | 1mg | 820 EUR |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
| MBS657133-5x1mg | MyBiosource | 5x1mg | 3470 EUR |
Linearity FLQ Special Diabetes for Abbott Systems |
|||
| K956M-5 | Audit MicroControls | 5 x 2 mL | 374 EUR |
Tissue, Section, Human Disease, Diabetes, Skin (Frozen) |
|||
| MBS640139-5Slides | MyBiosource | 5Slides | 755 EUR |
Also, a particular focus is tried to pool the databases concerning the medicinal crops for diabetes and related ailments, their bioactive compounds, attainable diabetic targets, drug-target interplay and toxicology experiences which will open an aisle in safer, efficient and toxicity-free drug discovery.